Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Assets: 2015-2024

Historic Other Non-Current Assets for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $10,000.

  • Spyre Therapeutics' Other Non-Current Assets fell 96.87% to $10,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $10,000, marking a year-over-year decrease of 96.87%. This contributed to the annual value of $10,000 for FY2024, which is 96.89% down from last year.
  • Spyre Therapeutics' Other Non-Current Assets amounted to $10,000 in FY2024, which was down 96.89% from $322,000 recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' Other Non-Current Assets ranged from a high of $1.8 million in FY2020 and a low of $10,000 during FY2024.
  • In the last 3 years, Spyre Therapeutics' Other Non-Current Assets had a median value of $322,000 in 2023 and averaged $628,333.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first grew by 22.80% in 2020, then crashed by 96.89% in 2024.
  • Spyre Therapeutics' Other Non-Current Assets (Yearly) stood at $1.8 million in 2020, then fell by 0.22% to $1.8 million in 2021, then fell by 15.51% to $1.6 million in 2022, then slumped by 79.27% to $322,000 in 2023, then tumbled by 96.89% to $10,000 in 2024.